Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rationale for the development of 2-aminobenzamide histone deacetylase inhibitors as therapeutics for Friedreich ataxia.

Journal of child neurology - 1 Sept 2012

Soragni Elisabetta, Xu Chunping, Plasterer Heather L, Jacques Vincent, Rusche James R, Gottesfeld Joel M

Abstract excerpt

Numerous studies have pointed to histone deacetylase inhibitors as potential therapeutics for various neurodegenerative diseases, and clinical trials with several histone deacetylase inhibitors have been performed or are under way. However, histone deacetylase inhibitors tested to date either are...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials, Phase I as Topic
Share to Fluorescent Dyes
Share to Frataxin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Friedreich Ataxia

Share to Histone Deacetylase Inhibitors

Share to Iron-Binding Proteins

Share to ortho-Aminobenzoates

Share to Trinucleotide Repeat Expansion

Source

Open in PubMed Open full text

Identifiers

PMID: 22764181
DOI: 10.1177/0883073812448533
PMCID: PMC3743553

Genes

FXN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-22764181-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rationale for the development of 2-aminobenzamide histone deacetylase inhibitors as therapeutics for Friedreich ataxia.PMID 22764181Read ↗

Translating HDAC inhibitors in Friedreich’s ataxiaSemantic proximity Read ↗

Increasing frataxin gene expression with histone deacetylase inhibitors as a therapeutic approach for Friedreich's ataxiaSemantic proximity Read ↗

Prolonged treatment with pimelic o-aminobenzamide HDAC inhibitors ameliorates the disease phenotype of a Friedreich ataxia mouse model.Semantic proximity Read ↗

Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia.Semantic proximity Read ↗

Epigenetic therapy for <scp>F</scp> riedreich ataxiaSemantic proximity Read ↗

Two New Pimelic Diphenylamide HDAC Inhibitors Induce Sustained Frataxin Upregulation in Cells from Friedreich's Ataxia Patients and in a Mouse ModelSemantic proximity Read ↗

Epigenetic and neurological effects and safety of high-dose nicotinamide in patients with Friedreich's ataxia: an exploratory, open-label, dose-escalation studySemantic proximity Read ↗

HDAC Inhibitors Correct Frataxin Deficiency in a Friedreich Ataxia Mouse ModelSemantic proximity Read ↗

Transcriptional profiling of isogenic Friedreich ataxia induced pluripotent stem cell-derived neuronsSemantic proximity Read ↗

The Friedreich ataxia GAA repeat expansion mutation induces comparable epigenetic changes in human and transgenic mouse brain and heart tissues.Semantic proximity Read ↗

Inhibition of the SUV4-20 H1 histone methyltransferase increases frataxin expression in Friedreich’s ataxia patient cellsSemantic proximity Read ↗

Small molecules affecting transcription in Friedreich ataxia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.